
Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer
Putting an emphasis on immunohistochemistry (IHC) staining is top of mind as fam-trastuzumab deruxtecan-nxki (Enhertu, T-DXd) sits alongside tisotumab vedotin-tftv (Tivdak) as options in the second-line cervical cancer setting. Unlike the tissue factor– …